Compare Biogen Inc (BIIB) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs GoPro Inc — how do they compare? Biogen Inc trades at $203.1 (market cap $30.13B), while GoPro Inc trades at $0.62 (market cap $114.41M). The key difference: Biogen Inc is far larger — about 263.4× GoPro Inc's market cap, and Biogen Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | GPRO | |
|---|---|---|
Market Cap | $30.13B | $114.41M |
Sector | Health | Technology |
52-Week High | $216.63 | $2.88 |
52-Week Low | $128.93 | $0.62 |
Enterprise Value | $37.20B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
GoPro (GPRO) trades at $0.70, down 3.53% in the last 24 hours, reflecting ongoing financial distress with a net income margin of -28.52% and negative cash flow. The stock is technically bearish, with moving averages signaling sell pressure, while recent news highlights a strategic review for a potential sale. Revenue has declined from $1.1B in 2022 to $652M in 2025, with consistent earnings misses and negative equity of -$681.61M.
The outlook hinges on the outcome of the strategic sale process, offering speculative upside if a buyer emerges, but risks include persistent cash burn, competitive pressures, and weak sales trends. Analysts are cautious, with only 21.43% recommending buy, as the company faces going-concern risks and dilution from financing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
